Skip to main content
    C

    Corbus Pharmaceuticals Holding (CRBP)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $3.38
    -0.02 (-0.44%)

    Market Cap: $69.86M

    Last updated: Nov 17, 2026 at 11:04 AM ET

    Corbus Pharmaceuticals Holding (CRBP) Financials: Revenue, Profit and Cash Flow

    Updated Nov 10, 2026. Financial statements from company filings, amounts in US dollars.

    Corbus Pharmaceuticals Holding reported revenue of $5.53M for the fiscal year ended Dec 31, 2025, down 12.4% from the year before. That year, net income was -$157.07M with a net margin of -2840.4%, operating cash flow was -$64.49M and free cash flow was -$64.50M. The quarter ended Sep 30, 2026 had revenue of $1.08M and net income of -$37.75M.

    Revenue and Margins

    Over the 9 years to Dec 2025, revenue grew from $1.91M, a compound annual rate of 12.5%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$5.53M-12.4%100.0%-1542.7%-2840.4%
    Dec 2024$6.31M+285.8%100.0%-772.0%-1274.3%
    Dec 2023$1.64MN/A100.0%-2755.4%-5452.8%
    Dec 2022$0-100.0%N/AN/AN/A
    Dec 2021$881.71K-77.6%100.0%-6350.1%-10352.8%
    Dec 2020$3.94M-89.1%100.0%-3119.2%-5652.2%
    Dec 2019$36.14M+649.5%100.0%-213.3%-197.7%
    Dec 2018$4.82M+97.6%100.0%-1176.8%-1154.5%
    Dec 2017$2.44M+27.7%100.0%-1334.4%-1328.6%
    Dec 2016$1.91MN/A100.0%-1045.6%-1046.3%
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, the net loss widened from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$5.53M$6.31M$1.64M$0$881.71K$3.94M$36.14M$4.82M$2.44M$1.91M
    Gross profit$5.53M$6.31M$1.64M$0$881.71K$3.94M$36.14M$4.82M$2.44M$1.91M
    Research and development$70.09M$32.22M$31.17M$16.14M$36.45M$98.27M$89.60M$48.61M$26.04M$15.44M
    Operating income-$85.31M-$48.72M-$45.08M-$39.84M-$55.99M-$122.81M-$77.10M-$56.75M-$32.56M-$19.99M
    Net income-$157.07M-$80.42M-$89.21M-$84.69M-$91.28M-$222.54M-$71.45M-$55.67M-$32.42M-$20.00M
    EBITDA-$78.52M-$38.44M-$40.82MN/A-$40.77M-$108.26M-$71.45M-$56.16M-$32.35M-$19.91M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$1.08M$1.16M$1.40M$1.41M$1.13M$1.31M$1.68M$4.71M$0$1.60M$0$1.64M
    Gross profit$1.08M$1.16M$1.40M$1.41M$1.13M$1.31M$1.68M$4.71M$0$1.60M$0$1.64M
    Operating income-$38.82M-$36.19M-$24.30M-$21.97M-$24.42M-$19.15M-$19.77M-$12.61M-$15.51M-$10.99M-$9.62M-$10.10M
    Net income-$37.75M-$35.04M-$45.94M-$41.11M-$23.34M-$17.66M-$33.96M-$19.06M-$27.57M-$19.99M-$13.80M-$16.04M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded short-term debt of $1.63M by $26.86M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$168.19M$155.88M$28.27M$66.31M$107.73M$102.29M$49.14M$46.99M$66.98M$17.89M
    Current assets$166.95M$152.98M$23.55M$60.18M$100.20M$92.07M$38.15M$44.24M$65.50M$17.40M
    Cash and equivalents$28.49M$17.20M$13.72M$17.00M$25.01M$85.43M$31.75M$41.75M$62.54M$14.99M
    Total liabilities$20.69M$13.45M$35.18M$33.32M$38.62M$57.02M$42.98M$19.47M$9.19M$8.97M
    Short-term debt$1.63M$0$301.00K$3.15M$3.86M$710.16K$752.66K$394.31K$332.86K$271.76K
    Long-term debtN/A$0N/A$15.98M$15.64M$18.03M$0N/A$0$5.00K
    Shareholder equity$147.50M$142.43M-$6.91M$32.99M$69.11M$45.27M$6.16M$27.52M$57.78M$8.92M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$122.90M$126.99M$144.48M$168.19M$109.51M$125.08M$139.93M$155.88M$164.17M$151.98M$125.74M$28.27M
    Total liabilities$38.14M$24.75M$18.14M$20.69M$17.37M$14.09M$12.82M$13.45M$13.67M$26.44M$28.78M$35.18M
    Cash and equivalents$30.25M$23.37M$25.66M$28.49M$26.98M$20.04M$18.90M$17.20M$19.42M$23.69M$14.10M$13.72M
    Shareholder equity$84.76M$102.24M$126.34M$147.50M$92.15M$110.99M$127.11M$142.43M$150.50M$125.54M$96.97M-$6.91M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow-$64.49M-$41.79M-$36.10M-$37.54M-$48.18M-$99.69M-$45.72M-$30.07M-$27.80M-$13.57M
    Capital expenditures$7.00K$0$0$13.45K$54.17K$484.49K$2.74M$2.30M$707.43K$353.03K
    Free cash flow-$64.50M-$41.79M-$36.10M-$37.56M-$48.24M-$100.17M-$48.46M-$32.37M-$28.50M-$13.92M
    Share repurchasesN/AN/A$0$0$1.82M$6.04M$2.57M$690.18K$2.94M$63.83K
    Investing cash flow-$1.64M-$121.31M$35.64M$30.07M-$73.42M-$484.49K-$2.74M-$2.30M-$707.43K-$353.03K
    Financing cash flow$77.43M$166.58M-$2.82M-$533.62K$60.82M$154.87M$38.46M$11.42M$76.01M$16.74M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$21.24M-$29.63M-$25.57M-$15.92M-$15.55M-$16.60M-$16.42M-$10.94M-$13.94M-$8.94M-$7.97M-$6.01M
    Capital expenditures$15.00K$6.00K$6.00K$7.00K$0$0$0$0$2$2$2$3
    Free cash flow-$21.25M-$29.63M-$25.58M-$15.93M-$15.55M-$16.60M-$16.42M-$10.94M-$13.94M-$8.94M-$7.97M-$6.01M
    Last 12 quarters

    Frequently Asked Questions About CRBP

    What is Corbus Pharmaceuticals Holding's annual revenue?

    Corbus Pharmaceuticals Holding reported revenue of $5.53M for the fiscal year ended Dec 31, 2025.

    How fast is Corbus Pharmaceuticals Holding's revenue growing?

    Revenue was down 12.4% for the fiscal year ended Dec 31, 2025 compared with the year before.

    Is Corbus Pharmaceuticals Holding profitable?

    No. Corbus Pharmaceuticals Holding reported net income of -$157.07M for the fiscal year ended Dec 31, 2025, with a net margin of -2840.4%.

    How much free cash flow does CRBP generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$64.49M minus capital expenditures of $7.00K produced free cash flow of -$64.50M.

    How much debt does Corbus Pharmaceuticals Holding have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $1.63M and cash and equivalents of $28.49M.